The European Medicines Agency (EMA) has revised its policy on access to EudraVigilance data for medicinal products for human use, issuing a comprehensive framework that delineates how various stakeholders may obtain and utilise information contained within the EudraVigilance database. The policy, adopted by the EMA Management Board in December 2015 with a minor technical update to Annex B in September 2016 and entering into force on 22 November 2017 following the launch of the new EudraVigilance system, establishes a proactive approach to data disclosure. It aims to support enhanced safety monitoring of authorised medicines, improve signal detection and evaluation of potential safety issues, bolster research activities and provide clearer information on suspected adverse reactions to healthcare professionals, patients and the public, all whilst ensuring strict compliance with European Union data protection legislation. Specific access rights are attributed to different user groups, including marketing authorisation holders, national medicines regulatory authorities in the European Economic Area, academic institutions, international bodies such as the World Health Organization and regulatory authorities outside the EU, with detailed requirements regarding access tools, data elements available and confidentiality undertakings. The revisions, which incorporate a summary of changes under Revision five as set out on page three of the document and further detail access to EudraVigilance data, underline the EMA's commitment to transparency, data security and the continuous improvement of pharmacovigilance practices within a robust regulatory framework.